IP Library Granted Patent US 7,157,097
Granted Patent B2
US 7,157,097 · App. 10/389,715 · Granted Jan 2, 2007

Penetration enhancing and irritation reducing systems

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,157,097
App. No.
10/389,715
Granted
Jan 2, 2007
Kind
B2
Abstract

This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Claims (46)

1. A composition for topical application having penetration-enhancing properties, said composition consisting essentially of:

a) an active agent, wherein said active agent is estradiol or derivatives thereof having a concentration in about 0.1% to about 10%;

b) a penetration-enhancing system consisting essentially of (i) a membrane fluidizer consisting essentially of oleic acid; (ii) a C 1 –C 4 alcohol; and (iii) a penetration enhancing glycol; and

c) a gelling agent, wherein said composition has a pH of about 4 to about 8.

2. The composition in accordance with claim 1 , wherein said active agent is estradiol.

3. The composition in accordance with claim 1 , wherein said active agent is present from about 0.1% to about 2% weight to weight of said composition.

4. The composition in accordance with claim 1 , wherein said active agent is present from about 1% to about 2% weight to weight of said composition.

5. The composition in accordance with claim 1 , wherein said oleic acid is present from about 0.1% to about 10% weight to weight of said composition.

6. The composition in accordance with claim 5 , wherein said oleic acid is present from about 0.1% to about 5% weight to weight of said composition.

7. The composition in accordance with claim 1 , wherein said C 1 –C 4 alcohol is a member selected from the group consisting of ethanol, propanol, isopropanol and mixtures thereof.

8. The composition in accordance with claim 7 , wherein said C 1 –C 4 alcohol is ethanol.

9. The composition in accordance with claim 7 , wherein said C 1 –C 4 alcohol is propanol.

10. The composition in accordance with claim 7 , wherein said C 1 –C 4 alcohol is isopropanol.

11. The composition in accordance with claim 7 , wherein said C 1 –C 4 alcohol is a mixture of ethanol and isopropanol.

12. The composition in accordance with claim 1 , wherein said C 1 –C 4 alcohol is present from about 5% to about 65% weight to weight of said composition.

13. The composition in accordance with claim 12 , wherein said C 1 –C 4 alcohol is present from about 10% to about 40% weight to weight of said composition.

14. The composition in accordance with claim 12 , wherein said C 1 –C 4 alcohol is present from about 25% to about 35% weight to weight of said composition.

15. The composition in accordance with claim 1 , wherein said glycol is a member selected from the group consisting of ethylene glycol, propylene glycol, butylene glycol and mixtures thereof.

16. The composition in accordance with claim 15 , wherein said glycol is ethylene glycol.

17. The composition in accordance with claim 15 , wherein said glycol is butylene glycol.

18. The composition in accordance with claim 15 , wherein said glycol is propylene glycol.

19. The composition in accordance with claim 15 , wherein said glycol is a mixture of ethylene glycol and butylene glycol.

20. The composition in accordance with claim 15 , wherein said glycol is a mixture of propylene glycol and butylene glycol.

21. The composition in accordance with claim 1 , wherein said glycol is present from about 25% to about 55% weight to weight of said composition.

22. The composition in accordance with claim 21 , wherein said glycol is present from about 30% to about 40% weight to weight of said composition.

23. The composition in accordance with claim 1 , wherein said gelling agent is a member selected from the group consisting of Carbopol 1342, Carbopol 940, Klucel and Klucel HF.

24. The composition in accordance with claim 23 , wherein said gelling agent is Carbopol 1342.

25. The composition in accordance with claim 1 , wherein said gelling agent is present from about 0.1% to about 10% weight to weight of said composition.

26. The composition in accordance with claim 25 , wherein said gelling agent is present from about 0.1% to about 5% weight to weight of said composition.

27. The composition in accordance with claim 25 , wherein said gelling agent is present from about 1% to about 3% weight to weight of said composition.

28. A transdermal patch, said transdermal patch consisting essentially of:

a) estradiol or a derivative thereof having a concentration of about 0.1% to about 2%; and

b) a penetration-enhancing system consisting essentially of: (i) oleic acid; (ii) a C 3 alcohol; and (iii) propylene glycol.

29. A composition for topical application having penetration-enhancing properties, said composition consisting essentially of:

a) an active agent, wherein said active agent is estradiol or derivatives thereof having a concentration of about 0.1% to about 2%;

b) a penetration-enhancing system consisting essentially of (i) oleic acid; (ii) and C 1 –C 4 alcohol; and (iii) a penetration enhancing glycol;

c) a gelling agent; and

d) an inert carrier, wherein said composition has a pH of about 4 to about 8.

30. The composition in accordance with claim 29 , wherein said composition has a pH value between about 5 to about 6.

31. A method for treating a menopausal or postmenopausal symptom, said method comprising: topically administering to a mammal a composition according to claim 1 , thereby treating said symptom.

32. The method in accordance with claim 31 , wherein said composition has a pH value of between about 5 to about 6.

33. The method in accordance with claim 31 , wherein said symptom is aging related changes to skin or mucous membranes.

34. The method in accordance with claim 31 , wherein said symptom is skin pigmentation.

35. The method in accordance with claim 31 , wherein said symptom is selected from skin roughness, wrinkles, furrows, fragility and atrophy.

36. The method in accordance with claim 31 , wherein said symptom is nail thinning.

37. The method in accordance with claim 31 , wherein said symptoms are hair thinning and/or fracturing.

Assignments (15)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Recorded Mar 24, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032513/0255 →
RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0157 →
CHANGE OF NAME Recorded Nov 17, 2011
From: STRAKAN INTERNATIONAL LIMITED
To: STRAKAN INTERNATIONAL S.A.R.L.
Reel/Frame 027247/0647 →
RELEASE OF PATENT SECURITY AGREEMENT Recorded Nov 10, 2011
From: MORGAN STANLEY BANK INTERNATIONAL LIMITED, AS SECURITY TRUSTEE
To: STRAKAN INTERNATIONAL LIMITED
Reel/Frame 027212/0299 →
RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172 Recorded Jul 12, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026577/0357 →
SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Jul 8, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026561/0978 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Dec 9, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025456/0172 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 23928/628 Recorded Dec 9, 2010
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 025456/0778 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Feb 13, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023928/0628 →
LICENSE Recorded Oct 30, 2009
From: STRAKAN INTERNATIONAL LIMITED
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 023449/0018 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2007
From: STRAKAN INTERNATIONAL LIMITED
To: MORGAN STANLEY BANK INTERNATIONAL LIMITED
Reel/Frame 019094/0323 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 21, 2007
From: STRAKAN INTERNATIONAL LIMITED
To: CELLEGY PHARMACEUTICALS, INC.
Reel/Frame 019035/0964 →
MERGER Recorded Feb 28, 2007
From: CELLEGY PHARMACEUTICALS, INC.
To: CELLEGY PHARMACEUTICALS, INC.
Reel/Frame 018942/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2007
From: CELLEGY PHARMACEUTICALS, INC.
To: STRAKAN INTERNATIONAL LIMITED
Reel/Frame 018934/0497 →
SECURITY INTEREST Recorded Sep 29, 2006
From: CELLEGY PHARMACEUTICALS, INC.
To: STRAKAN INTERNATIONAL LIMITED
Reel/Frame 018338/0001 →